Home › Employers › Dipna RX Inc.
Dipna RX Inc.: H-1B salaries and sponsorship
Dipna RX Inc. filed 5 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $81,000.
Does Dipna RX Inc. sponsor H-1B visas?
Dipna RX Inc. filed 5 labor condition applications in fiscal years 2023–2026, the latest submitted on Apr 13, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Market Research Analyst | 3 | $90,000 |
| Analytical Chemist | 2 | $81,000 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 1 | $81,000 |
| FY2025 | 3 | $90,000 |
| FY2026 | 1 | $81,000 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Analytical Chemist | $81,000 Level II | Bronx, NY | Apr 13, 2026 | Aug 22, 2026 | Certified |
| Market Research Analyst | $90,000 Level II | Bronx, NY | Oct 7, 2024 | Dec 31, 2024 | Certified |
| Market Research Analyst | $90,000 Level II | Bronx, NY | Oct 7, 2024 | Dec 31, 2024 | Withdrawn |
| Market Research Analyst | $90,000 Level II | Bronx, NY | Oct 7, 2024 | Jan 1, 2025 | Withdrawn |
| Analytical Chemist | $81,000 Level II | Bronx, NY | Mar 20, 2023 | Aug 22, 2023 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).